LEXINGTON, Mass., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its fourth quarter financial results on Wednesday, February 8, 2012, before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) Erivedge (vismodegib), a hedgehog pathway inhibitor under collaboration with Genentech that is the first and only FDA-approved medicine for people with advanced forms of basal cell carcinoma, (ii) CUDC-101, CUDC-907, Debio 0932 and other network-targeted cancer programs, (iii) its financial results as of and for the fourth quarter and fiscal year ended December 31, 2011, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
